Medicines run short in Iran under US sanctions

by@FT

Summary

Iran is facing severe medicine shortages as US sanctions continue to impede international payments and insurance for medication imports despite exemptions for humanitarian goods. These shortages are compounded by ongoing regional conflicts that have damaged pharmaceutical production facilities and disrupted maritime shipping routes for essential raw materials. As a result, many patients are left struggling to find adequate treatments for chronic and serious conditions, often opting for generics or reduced doses amid increasing costs.

Analysis

Iran: Iran is a country in Western Asia whose economy and healthcare system are currently strained by US sanctions under President Trump's maximum pressure campaign. These measures target banking and oil exports, complicating access to foreign currency needed for imports. Recent conflicts and shipping restrictions have further disrupted the procurement of pharmaceutical raw materials, exacerbating medicine shortages nationwide. Healthcare Strain: Shortages affect treatments for chronic and serious conditions, forcing patients toward generics or reduced doses amid rising costs. Sanctions Effects: US sanctions hinder international payments and insurance for medicine imports even when humanitarian goods are formally exempt. Supply Chain Disruptions: Ongoing regional conflicts have damaged pharmaceutical production facilities and restricted maritime shipping routes for raw materials.

Categories

predictionsmacropolitics

Related sources

View Original Tweet